Tag
A Mayo Clinic AI model detected early signs of pancreatic cancer on imaging scans up to two years before patients received a formal diagnosis. Because pancreatic cancer is rarely caught early, a reliable pre-diagnostic screening tool could significantly improve survival rates for one of the deadliest common cancers.
Revolution Medicines announced Phase 3 data showing daraxonrasib extended median survival to 13.2 months in advanced pancreatic adenocarcinoma versus 6.7 months on standard chemotherapy. The near-doubling of survival in one of oncology's hardest-to-treat cancers positions Revolution for an FDA approval filing. No
Allogene Therapeutics CMO Zach Roberts presented new study results for the company's off-the-shelf CAR-T therapy targeting B-cell lymphoma, an allogeneic approach that bypasses patient-specific cell manufacturing. If validated further, the model could lower treatment costs and shorten time to therapy versus
Tag
A Mayo Clinic AI model detected early signs of pancreatic cancer on imaging scans up to two years before patients received a formal diagnosis. Because pancreatic cancer is rarely caught early, a reliable pre-diagnostic screening tool could significantly improve survival rates for one of the deadliest common cancers.
1mo ago · 3 min · Technology
Revolution Medicines announced Phase 3 data showing daraxonrasib extended median survival to 13.2 months in advanced pancreatic adenocarcinoma versus 6.7 months on standard chemotherapy. The near-doubling of survival in one of oncology's hardest-to-treat cancers positions Revolution for an FDA approval filing. No
2mo ago · 1 min · Technology
Allogene Therapeutics CMO Zach Roberts presented new study results for the company's off-the-shelf CAR-T therapy targeting B-cell lymphoma, an allogeneic approach that bypasses patient-specific cell manufacturing. If validated further, the model could lower treatment costs and shorten time to therapy versus
2mo ago · 1 min · Technology
— End of feed —